Clinical Trials Logo

Meningeal Carcinomatosis clinical trials

View clinical trials related to Meningeal Carcinomatosis.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT04315246 Withdrawn - Solid Tumor, Adult Clinical Trials

177Lu-DTPA-Omburtamab Radioimmunotherapy for Leptomeningeal Metastasis From Solid Tumors (Breast, NSCLC, Malignant Melanoma)

Start date: August 31, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

Adults with leptomeningeal metastasis from solid tumors will be treated with 177Lu-DTPA-omburtamab, which is a radioactive labelling of a murine monoclonal antibody targeting B7-H3.

NCT ID: NCT03974204 Withdrawn - Breast Cancer Clinical Trials

Analyses of Exosomes in the Cerebrospinal Fluid for Breast Cancer Patients With Suspicion of Leptomeningeal Metastasis.

Start date: July 2019
Phase: N/A
Study type: Interventional

This is a multicenter, interventional, prospective study among breast cancer patients with a suspicion of metastatic meningitis. The current study aims to assess the use of proteomic profile issued from cerebrospinal fluid microvesicles for diagnosis of leptomeningeal metastases.

NCT ID: NCT01438021 Withdrawn - Clinical trials for Leptomeningeal Metastases

Continuous Intraventricular Methotrexate in Treating Patients With Leptomeningeal Disease

Start date: September 2012
Phase: N/A
Study type: Interventional

This pilot clinical trial studies continuous intraventricular methotrexate in treating patients with leptomeningeal disease. Drugs used in chemotherapy, such as methotrexate, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving drugs directly into the ventricles may be an effective treatment for patients with leptomeningeal disease

NCT ID: NCT00210340 Withdrawn - Lymphoma, B Cell Clinical Trials

A Phase I Study of Intrathecal Rituximab in Patients With Lymphomatous Meningitis

Start date: n/a
Phase: Phase 1
Study type: Interventional

The purpose of this study is to define the safety profile of rituximab given intrathecally in lymphomatous meningitis related to CD20+ non-Hodgkin's lymphomas.